A new cancer drug from Merck has helped people with advanced stomach and esophageal cancers live longer, according to results from a large international trial announced on Friday, 20 November.
The drug, called sacituzumab tirumotecan, or sac-TMT, met its main goal of improving overall survival in patients with locally advanced or metastatic gastroesophageal adenocarcinoma who had already received two or more previous courses of treatment. It is the first time a drug of its kind, a TROP2-directed antibody-drug conjugate, has shown a survival benefit in a global phase 3 trial in this group of patients.
That is a significant result in one of the hardest areas of cancer medicine. Cancers of the stomach and esophagus, the tube that carries food from the mouth to the stomach, are often found late, and once they have spread, they are very difficult to treat. Patients who have already been through two or more lines of therapy have usually run out of good options. Chemotherapy can still help some of them, but the benefits tend to be modest, and the side effects are often hard to bear. A new treatment that extends life in this setting, even by a little, is something doctors and patients pay close attention to.
The trial, called TroFuse-015, enrolled 473 patients around the world. Half of them received sac-TMT, given at a dose of 4 milligrams per kilogram on days one, 15 and 29 of each six-week cycle. The other half received a treatment chosen by their own doctor, from a list of standard chemotherapies: trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel.
At the final analysis, patients who received sac-TMT lived significantly longer than those who received their doctor’s choice of chemotherapy. Merck described the improvement as both statistically significant and clinically meaningful, which means it was large enough to matter in real life, not just on paper. The results were generally consistent across subgroups, regardless of whether the patients’ tumours expressed high or low levels of TROP2, the protein the drug is designed to target.
There is, however, a complication in the picture that doctors will want to understand. The trial did not meet its secondary goal of improving progression-free survival, the length of time before the cancer starts growing again, as judged by independent reviewers who did not know which treatment patients had received. The response rate, the share of patients whose tumours shrank, did favour sac-TMT, but that comparison was not formally tested under the trial’s pre-set analysis plan, so it cannot be treated as a proven result. In short, patients lived longer, but their tumours did not obviously stop growing for longer, and did not obviously shrink more often.
That sounds contradictory, and it is the kind of result that oncologists will argue about until the full numbers are published. It is not unheard of in cancer trials, particularly with immunotherapies, for a drug to extend life without clearly delaying the growth of tumours on scans. As analysts at RBC Capital Markets noted in a note to investors, overall survival remains the gold standard in this setting, and it is the measure that matters most to patients.
What is missing, for now, is the size of the benefit. Merck did not disclose any numbers: no median survival times, no hazard ratio, no confidence interval, no p-value. Without those figures, it is impossible to say whether patients lived weeks longer or months longer, and impossible to weigh the benefit against the side effects. The company said the detailed results will be presented at an upcoming medical meeting and shared with regulatory authorities, and until then, the announcement is a promise rather than a proof.
The safety profile, Merck said, was consistent with earlier studies of sac-TMT, with no new safety signals. That is reassuring as far as it goes, but the details have not been published yet. Antibody-drug conjugates, the class of drug sac-TMT belongs to, work by attaching a powerful chemotherapy drug to an antibody that seeks out a specific protein on cancer cells. The idea is to deliver the poison directly to the tumour and spare the rest of the body. In practice, they still cause side effects, and the balance between benefit and harm is something doctors can only judge once they have seen the full data.
For Merck, the result is the second positive phase 3 readout from its TroFuse programme, a large development effort built around sac-TMT that now includes 18 ongoing global phase 3 trials across more than nine disease areas, including endometrial, bladder, breast, cervical, gastric, lung and ovarian cancers. The drug was licensed from Kelun-Biotech, a Chinese company that discovered it, and it is already approved in four indications in China. In the United States, it is under priority review by the Food and Drug Administration for previously treated endometrial cancer, with a decision expected by June 2027. The stomach and esophageal result, if it holds up, would add another important use.
“Sac-TMT is the first TROP2 ADC to improve OS in a global Phase 3 study in advanced gastroesophageal adenocarcinoma compared to TPC, demonstrating its potential in a particularly challenging disease setting,” said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, at Merck Research Laboratories. It is the kind of statement drug companies make when a trial succeeds, and it is true as far as it goes. But the history of cancer drug development is full of announcements that looked better, or worse, once the numbers came out.
For patients with advanced stomach and esophageal cancer, the news is hopeful but not yet practical. Sac-TMT is not available for this use, and it will not be until regulators have reviewed the full data and decided whether the benefit is worth the risks. That process takes time, and the full results have not even been presented yet. What the announcement does offer is a sign that a new kind of treatment, one that targets a protein found on many of these tumours, can extend life where existing treatments have offered so little.
Stomach and esophageal cancers kill hundreds of thousands of people every year, and they attract less research funding and less public attention than breast or lung cancer. A survival benefit in a global trial, in patients who had already exhausted other options, is a genuine step forward. The next step is to see the numbers, and to find out how big that step really is.
